Benjamin Negin, MD
Internal Medicine · Vineland, NJNPI 1366477697
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 784 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.9% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 784 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novartis$917
- Pfizer$715
- Genentech USA, Inc.$565
- GSK$469
- Bristol Myers Squibb$449
- plus $8K from 54 others
Across 19 payments — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmacyclics LLC, An Abbvie Company$3K
What the payments were for
- Food & beverage$12,86799%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,935 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KeytrudaPembrolizumab | 71 | $789,339 |
| IbrancePalbociclib | 25 | $384,827 |
| PromactaEltrombopag Olamine | 35 | $379,737 |
| PomalystPomalidomide | 16 | $374,281 |
| NeulastaPegfilgrastim | 42 | $311,590 |
| CalquenceAcalabrutinib Maleate | 19 | $267,537 |
| XtandiEnzalutamide | 21 | $254,908 |
| ImfinziDurvalumab | 22 | $254,500 |
| RevlimidLenalidomide | 13 | $228,268 |
| Lenalidomide | 16 | $217,574 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $217,058 |
| EliquisApixaban | 207 | $200,850 |
| JemperliDostarlimab-Gxly | 14 | $160,881 |
| JakafiRuxolitinib Phosphate | 14 | $158,315 |
| VenclextaVenetoclax | 13 | $148,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckKeytruda | $400 | $789,33971 claims |
| NovartisPromacta, Mekinist, Tafinlar | $917 | $647,04559 claims |
| PfizerIbrance, Eliquis, Octagam | $715 | $636,419245 claims |
| AstraZenecaCalquence, Imfinzi | $1,027 | $522,03741 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $445 | $374,28116 claims |
| AmgenNeulasta | $106 | $311,59042 claims |
| Astellas Pharma US IncXtandi | $259 | $254,90821 claims |
| Bristol Myers SquibbRevlimid | $449 | $228,26813 claims |
| GSKJemperli | $469 | $160,88114 claims |
| Incyte CorporationJakafi | $247 | $158,31514 claims |
| AbbVieVenclexta | $304 | $148,21713 claims |
| Johnson & JohnsonXarelto, Procrit | $396 | $134,618102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Vineland
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.